Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria

  • Hassan, A.A. (Department of Zoology, University of Ibadan) ;
  • Akinsanya, B. (Department of Zoology, University of Lagos) ;
  • lyase, N. (Department of Zoology, University of Ibadan) ;
  • Owagboriaye, F.O. (Department of Plant Science and Applied Zoology, Olabisi Onabanjo University)
  • Received : 2010.11.22
  • Accepted : 2011.03.26
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

A total of 286 individuals from 3 selected communities (Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo) of Ijebu-North, southwestern Nigeria were examined for Loa loa microfilaremia using finger prick blood smear, between December 2008 and March 2009. Rapid assessment procedure for loiasis (RAPLOA) was used to obtain information, from 187 Ijebu-Igbo residents, on adverse reactions experienced from retrospective treatments with ivermectin and history of eye worm. Only 33.9% of the respondents reported having had a history of eye worm while 33.2% had microfilaremia. The demographic factor of gender was not significant determinants of the prevalence (p>0.05) while age was significant (P<0.05). The highest prevalence of eye worm history and microfilaremia were recorded in 61-70 and 15-20 years of age categories, respectively. Ijebu-Igbo had 27.3% eye worm history, 32.1% microfilaremia, and the highest intensity of 140 microfilariae (mf)/ml. Ipakodo area had the highest eye worm history of 54.4% and the highest intensity of 420 mf/ml. Areedi-Aje had the highest occurrence of 45.2% microfilaremia and the highest intensity of 460 mf/ml. Predictably, Areedi-Aje and Ipakodo areas were high risk communities. The low intensity of L. loa infection with an insignificant (2.1%; P>0.05) adverse reactions from 187 subjects involved in the retrospective ivermectin administration confirmed that ivermectin delivery may be considered safe. The community-directed treatment with ivermectin (CDTI) programme was most probably responsible for the low prevalence and intensity.

Keywords

References

  1. Kyari F, Gudlavalleti MV, Sivsubramaniam S, Gilbert CE, Abdull MM, Entekume G, Foster A. Prevalence of blindness and visual impairment in Nigeria: the National Blindness and Visual Impairment Study. Invest Ophthalmol Vis Sci 2009; 50: 2033-2039. https://doi.org/10.1167/iovs.08-3133
  2. Ashaye AO. Glaucoma blindness: facts, fancies and fables. 12th Faculty of Ophthalmology Lecture, National Postgraduate Medical College of Nigeria. 2010, p 48.
  3. The $Mectizan^{\circledR}$ Expert Committee/The $Mectizan^{\circledR}$Donation Program. Recommendations for the treatment of onchocerciasis with $Mectizan^{\circledR}$ in areas co-endemic for onchocerciasis and loiasis 2004.
  4. World Health Organization. "A New Drug for River Blindness?" www.who.int/tdr/ir/moxidectin.pdf 2007.
  5. Ogunba EO. Loiasis in Ijebu division, West Nigeria. Trop Geog Med 1971; 23: 194-200.
  6. Ogunba EO. Ecology of human loiasis in Nigeria. Trans R Soc Trop Med Hyg 1972; 66: 743-748. https://doi.org/10.1016/0035-9203(72)90088-0
  7. Oyerinde JPO, Odugbemi T, Fagbenro-Beyioku AF. Investigation of filarial worms of man in metropolitan Lagos. Acta Trop 1988; 45: 191-192.
  8. Agbolade OM, Akinboye DO. Loiasis and some haematological parameters in Ijebu-North area of Ogun State, Nigeria. Bull Sci Ass Nig 2000; 23: 29-32.
  9. Agbolade OM, Akinboye DO. Loa loa and Mansonella perstans infections in Ijebu-North, Western Nigeria; a Parasitological Study. Jpn J Infect Dis 2001; 54: 108-110.
  10. Agbolade OM, Akinboye DO, Ogunkolo OF. Loa loa and Mansonella perstans: neglected human infections that need control in Nigeria. Afr J Biotech 2005; 4: 1554-1558.
  11. Adeoye GO, Akinsanya B, Otubanjo AO, Ibidapo CA, Afolabi T, Okwuzu I, Adejai EO, Braide EEI. Prevalence of loiasis in Ondo State, Nigeria, as assessed by the rapid assessment procedure for loiasis (RAPLOA). Ann Trop Med Parasitol 2008; 102: 215-227. https://doi.org/10.1179/136485908X267867
  12. Chippaux JP, Boussinesq M, Gardon JN, Gardon-Wendel N, Ernould JC. Severe adverse reaction risk during mass treatment with ivermectin in loiasis- endemic areas. Parasitol Today 1996; 12: 448-450. https://doi.org/10.1016/0169-4758(96)40006-0
  13. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after treatment of onchocerciasis with ivermectin in an endemic area for Loa loa infection. Lancet 1997; 350: 18-22. https://doi.org/10.1016/S0140-6736(96)11094-1
  14. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno P, Ngoumou P, Chippaux JP. Three probable causes of Loa loa encephalopathy following ivermectin treatment for onchocersiasis. Am J Trop Med Hyg 1998; 58: 461-469. https://doi.org/10.4269/ajtmh.1998.58.461
  15. Kipp W, Bamhuhiiga J, Rubaale T, Buttner DW. Adverse reaction to ivermectin treatment in Simulium neavei - transmitted onchocersiasis. Am J Trop Med Hyg 2003; 69: 621-623.
  16. Oyibo WA, Fagbenro-Beyioku AF. Adverse reaction following annual ivermectin treatment of onchocerciasis in Nigeria. Int J Infect Dis 2003; 7: 156-159. https://doi.org/10.1016/S1201-9712(03)90013-0
  17. World Health Organisation. Report of a multi-country study: the involvement of community-directed distributors of ivermectin in other health and development activities. UNDP/World Bank /WHO TDR/ IDE/CDDI/D3.1 2003.
  18. World Health Organization. Guidelines for Rapid Assessment of Loa loa. Doc TDR/IDE/RAPLOA/021. Geneva:WHO 2002.
  19. Brown BA. Haematology: Principles and Procedures. 3rd ed. England. Lea and Febiger. 1980.
  20. Orihel TC, Ash LR, Ramachandran CP, Ottensen EA. Bench Aids for the Diagnosis of Filarial Infections: Geneva World Health Organization 1997.
  21. Ranque S, Garcia A, Boussinesq M, Gardon NJ, Kamgno J, Chippaux JP. Decreased prevalence and intensity of Loa loa infection in a community treated with ivermectin every three months for two years. Trans R Soc Trop Med Hyg 1996; 90: 429-430. https://doi.org/10.1016/S0035-9203(96)90535-0
  22. Hodgkin C, Molyneux DH, Abiose A, Philippon B, Reich MR, Remme JH, Thylefors B, Traore M, Grepin K. The future of onchocerciasis control in Africa. PLoS Negl Trop Dis 2007; 1: e74. https://doi.org/10.1371/journal.pntd.0000074
  23. Pion SDS, Demanou B, Oudi N, Boussinesq M. Loiasis: the individual factors associated with the presence of microfilaremia. Ann Trop Med Parasitol 2005; 99: 491-500. https://doi.org/10.1179/136485905X51300
  24. Tropical Diseases Research News. Keynote Article. Loa loa: a new rapid assessment tool. TDR News 2001; 66: 1-2.
  25. World Health Organization. Rapid Assessment Procedures for Loiasis. www.who.int/tdr/cdpublicaions/pdf/raploa.pdf 2001.
  26. Anosike JC, Onwuliri CO. Studies on filariasis in Bauchi State, Nigeria: the prevalence of human filariasis in Darazo local government area. Appl Parasitol 1994; 35: 242-250.
  27. Udonsi JK. Filariasis in Igwun River Basin, Nigeria: an epidemiological and clinical study with a note on the vectors. Ann Trop Med Parasitol 1988; 82: 75-82. https://doi.org/10.1080/00034983.1988.11812212
  28. Ash LR. Preferential susceptibility of male jirds (Meriones unguiculatus) to infection with Brugia pahangi. J Parasitol 1971; 57: 777-780. https://doi.org/10.2307/3277796
  29. Pion SDS, Gardon NJ, Kamgno J, Gardon-Wendel N, Chippaux JP, Boussinesq M. Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the programmes of community-directed treatment with ivermectin carried out in Africa. Parasitology 2004; 129: 613-629. https://doi.org/10.1017/S0031182004005694
  30. Garcia A, Abel L, Cot M, Ranque S, Richard P, Boussinesq M, Chippaux JP. Longitudinal survey of Loa loa filariasis in Southern Cameroon: long-term stability and factors influencing individual microfilarial status. Am J Trop Med Hyg 1995; 52: 370-375. https://doi.org/10.4269/ajtmh.1995.52.370
  31. Pinder M, Duport A, Egwag TG. Identification of a surface antigen on Loa loa microfilaraemic state in man. J Immunol 1988; 141: 2480-2486.
  32. Martin-Prevel Y, Cosnefroy J, Tshipamba P, Ngari P, Chodakewitz JA, Pinder M. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg 1993; 48: 186-192. https://doi.org/10.4269/ajtmh.1993.48.186
  33. Burnham GM. Adverse reactions to ivermectin treatment for onchocerciasis: results of a placebo-controlled, double-blind trial in malaria. Trans R Soc Trop Med Hyg 1993; 87: 313-317. https://doi.org/10.1016/0035-9203(93)90144-F
  34. Duong TH, Kombila M, Ferrer A, Bureau P, Gaxotte P, Richard-Lenoble D. Reduced Loa loa microfilaria count ten to twelve months after a single dose of ivermectin. Trans R Soc Trop Med Hyg 1997; 91: 592-593. https://doi.org/10.1016/S0035-9203(97)90040-7
  35. Pinder M. Loa loa-a neglected filaria. Parasitol Today 1988; 4: 279-284. https://doi.org/10.1016/0169-4758(88)90019-1
  36. Wahl G, Georges AJ. Current knowledge on the epidemiology, diagnosis, immunology and treatment of loiasis. Trop Med Parasitol 1995; 46: 287-291.

Cited by

  1. A Case of Loiasis in a Patient Returning to China Diagnosed by？Nested PCR Using DNA Extracted From Tissue vol.19, pp.5, 2011, https://doi.org/10.1111/j.1708-8305.2012.00635.x
  2. In Southern Nigeria Loa loa Blood Microfilaria Density is Very Low Even in Areas with High Prevalence of Loiasis: Results of a Survey Using the New LoaScope Technology vol.99, pp.1, 2011, https://doi.org/10.4269/ajtmh.18-0163